AnaCardio
AnaCardio is a privately held clinical stage biopharmaceutical company developing novel drugs to treat heart failure.
AnaCardio has raised €77M across 2 funding rounds from 12 investors, most recently a Series B round in Sep 2026. Based in Stockholm, Sweden; active in Healthtech. Data as of 28 Oct 2026.
Stockholm, Swedenwww.anacardio.com ↗
Total raised
€77M
€76,565,621
Funding rounds
2
Investors
12
distinct backers
Active since
2022-09
latest 2026-09
Funding by year
EUR raised per year · 2026 YTDAnaCardio — funding by year — interactive chart.
Data table
| AnaCardio — funding by year | |
|---|---|
| 2022 | €14M |
| 2026 | €63M |
Signals
High confidenceRaise-next likelihood20
base rate 48% for Series B
- ▼ Raised very recently
- ▲ Up-round momentum
- ▼ Low backer re-investment
Exit likelihood20
base rate 11% (2+ rounds)
- ▲ €30M+ raised
- ▲ Recently backed by strong-exit-track investors
Timing: too soon vs cohort gap · momentum up. Funding-only estimates, not predictions and not investment advice — see signals.
Funding rounds
2 rounds| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2026-09-30 | Series B | €63M | Flerie Invest,Helsinn Investment Fund,Industrifonden,Innovestor Life Science Fund,Ljungström family office,LLD Nybohov Invest AB+3 more | View deal → |
| 2022-09-09 | Series A | €14M | 3B Health Ventures,Flerie Invest,Fredrik and Ann-Helene Ljungström,Industrifonden,Karolinska Development | View deal → |